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AbstrACt
Introduction Mild cognitive impairment (MCI) is 
common in older adults and represents a high-risk group 
for progression to Alzheimer’s disease (AD). Medication 
trials in MCI have generally failed, but new discoveries 
with brain plasticity in ageing have led to the study of 
cognitive training as a potential treatment to improve 
cognitive abilities. Computerised cognitive training 
(CCT) involves computerised cognitive exercises that 
target specific cognitive abilities and neural networks 
to potentially improve cognitive functioning through 
neuroplasticity.
Methods and analysis In a two-site study (New York 
State Psychiatric Institute/Columbia University Medical 
Center and Duke University Medical Center), we will 
randomise 100 patients with MCI (Wechsler Memory 
Scale-III Logical Memory II score 0–11; Folstein Mini 
Mental State Examination ≥23) to home-based CCT (suite 
of exercises: memory, matching, spatial recognition, 
processing speed) or a home-based active control 
condition (computerised crossword puzzle training (CPT)) 
with 12 weeks of intensive training followed by regular 
booster sessions up to 78 weeks. All patients will receive 
standard neuropsychological and functional assessments 
in clinic as well as structural/functional brain MRI scans 
at study entry and endpoint. We will test if CCT, versus 
CPT, leads to improved cognitive functioning, transfers to 
functional ability and tasks of everyday life and impacts 
hippocampal volume changes and changes in the default 
mode network of the brain measured by resting-state 
functional MRI.
Ethics and dissemination The study will be conducted 
following ethics approval and written informed consent 
will be obtained from all subjects. Study results will be 
disseminated via publication,  clinicaltrials. gov, media and 
conference presentations. This will be the first controlled 
long-term trial to evaluate the effects of home-based 
CCT versus computerised CPT on cognitive abilities and 
functional measures and neural outcomes as determined 
by MRI indices in patients with MCI. Positive results from 
trial may support further development of home-based CCT.
trial registration number  ClinicalTrials. gov identifier 
(NCT03205709).
IntroduCtIon
Alzheimer’s disease (AD) is a major public 
health concern affecting over 40 million 
people worldwide, and there is an urgent 
need to develop new treatment modalities 
strengths and limitations of this study
 ► The study will improve on limitations of most previ-
ous studies by including an ‘active’ control condition 
rather than waitlist or control conditions that do not 
account for engagement and motivation.
 ► This study will evaluate performance on tradi-
tional cognitive and functional assessments (eg, 
Alzheimer’s Disease Assessment Scale-Cognition 
Subscale 11, University of California San Diego 
Performance-Based Skills Assessment) in addition 
to performance on a self-administered, computer-
ised cognitive test, the NeuroCognitive Performance 
Test, which consists of 10 subtests that are online 
adaptations of widely used neuropsychological tests.
 ► The trial will use a remote Internet-based computer-
ised cognitive training (CCT) intervention that can be 
done at home; compared with most existing treat-
ments under investigation, it is easily accessible, 
relatively inexpensive, non-invasive and scaled to 
the skill level of each individual.
 ► The trial will include evaluation of clinically relevant 
genetic, brain network and neuronal loss markers 
as moderators of outcome; this will be one of the 
first trials to examine long-term effects on cogni-
tion, daily functioning and neuroplastic changes in 
default mode network with CCT in mild cognitive 
impairment.
 ► As our trial will be restricted to English-speaking 
participants because the online training platform is 
only available in English, we are unsure how this will 
generalise to non-English speaking individuals. In 
addition, the inclusion criteria state that the partici-
pant must have an at-home desktop or laptop com-
puter, which, in low socioeconomic class homes, is 
not always available.
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to prevent or delay the onset of dementia. Mild cogni-
tive impairment (MCI) is common in older adults and 
represents a high-risk group for AD, but medication trials 
in MCI have generally failed. There is no Food and Drug 
Administration-approved treatment for MCI or to prevent 
the progression of MCI to AD.
There is growing evidence that a cognitively active life-
style may reduce rates of dementia. A systematic review of 
22 population-based studies found that mental activities 
may reduce overall incident dementia risk by 46% over a 
median 7-year period.1 Computerised cognitive training 
(CCT) provides a novel strategy to improve cognitive 
performance in MCI by establishing a more cognitively 
active lifestyle. CCT involves computerised cognitive 
exercises that target specific abilities to improve cogni-
tive functioning, and this effect is likely to be mediated 
by neuroplasticity. CCT has been used successfully to 
improve cognitive functioning in healthy adult popula-
tions.2–5 In particular, two studies in older healthy controls 
have garnered much attention. The Advanced Cognitive 
Training for Independent and Vital Elderly (ACTIVE) 
trial was the first large-scale, randomised trial to show 
evidence of transfer from cognitive training to improved 
daily function, but only in participants who completed 
reasoning or speed of processing focused training and 
not memory training.6 In this 10-year follow-up study 
of 2,832 healthy adults (average age=73.6), participants 
were randomised to one of three intervention groups 
(memory, reasoning or speed of processing) or a no-con-
tact control group. Booster sessions occurred for 39% of 
participants in all active groups at 11 and 35 months after 
initial training, but the cognitive effects of the memory 
training did not persist over the 10-year follow-up period.6 
In a second large, well-publicised online cognitive 
training study, findings were originally considered to be 
negative in terms of cognitive gains. However, in an exam-
ination of an older subsample, training was effective in 
improving cognitive abilities and instrumental activities 
of daily living.7
In a recent meta-analysis examining CCT in older 
adults with MCI or dementia, the overall efficacy of 
cognitive outcomes in MCI was moderate and statistically 
significant.8 This pattern was also found for global cogni-
tion, verbal learning and memory, non-verbal learning, 
working memory, attention and psychosocial functioning 
(eg, depression, quality of life, neuropsychiatric symp-
toms). However, for the efficacy of cognitive outcomes in 
patients with dementia, the overall effect was found to be 
small, though statistically significant.
Early interventions at the stage of MCI, and not 
dementia, may be more helpful for improving cognition. 
In fact, Hill et al8 concluded that CCT is a feasible inter-
vention for improving cognition in patients with MCI. 
Transfer effects have also been found in studies evaluating 
CCT in healthy older adults, supporting the potential 
for transfer of CCT benefits to daily life.6 9 In this study, 
we will assess for transfer effects by administering the 
following functional assessments at specific timepoints: 
Functional Activities Questionnaire (FAQ) and University 
of California San Diego Performance-Based Skills Assess-
ment (UPSA).
Although CCT has received more support in the past 
few years as a viable treatment option for older adults 
with MCI, the brain mechanisms underlying the observed 
cognitive changes remain elusive. Many studies of CCT that 
include imaging components have only been conducted 
with healthy older adults.10–13 CCT may promote neuro-
plasticity in the brain, including in the hippocampus, a 
key region that supports memory.13–16 Additional research 
needs to be done that evaluates both structural and func-
tional data within a rigorously conducted clinical trial. 
In this study, patients will undergo a structural MRI and 
functional MRI (fMRI) at both study entry and exit to 
assess for changes in hippocampal volume and the default 
mode network (DMN). The latter is crucial to evaluate in 
patients with MCI as dysfunction in the DMN has been 
implicated in the progression of MCI to AD.17 The DMN 
is a resting state neural network of several highly intercon-
nected cortical hubs, including the posteromedial parietal, 
anteromedial frontal and inferolateral parietal cortices. 
We have shown that impaired deactivation and functional 
connectivity in the DMN may be a significant predictor 
in MCI of poor memory and transition to dementia 
over a 2–3 year follow-up period.18 Neuronal dysfunction 
precedes structural atrophy in AD, and fMRI offers the 
potential for identifying specific patterns of disruption in 
the memory networks affected early in MCI and AD.
Limitations of prior CCT trials include the inconsis-
tent demonstration of transfer to everyday functioning, 
reliance on waitlist control conditions as opposed to 
active control conditions and lack of long-term follow-up. 
Most studies have not assessed transfer of cognitive 
improvement to everyday function or quality of life.19–23 
While CCT may produce transfers to untrained cogni-
tive domains, the few studies that evaluate transfer to 
everyday functioning have reported mixed findings.24–29 
This is particularly important given the strong associa-
tion between cognitive decline and functional disability.30 
Many studies use waitlist control conditions or control 
conditions that do not account for engagement and moti-
vation in the task.22 Such designs are biassed in favour 
of the treatment condition because waitlisted subjects are 
not receiving any form of cognitive treatment and, there-
fore, may be more likely to drop out of such studies due to 
lack of engagement and motivation. In the current study, 
patients will be assigned to one of two cognitively stim-
ulating exercises, CCT (suite of exercises) or crossword 
puzzle training (CPT; crossword puzzles). Since one of 
the purposes of CCT in patients with MCI is to reduce the 
risk of progression to dementia, longer follow-up times are 
necessary to be able to accurately capture patient progres-
sion. However, most studies have only used no follow-up 
or short-term follow-ups, with the notable exception of 
the ACTIVE trial.6 31–33
Overall, recent findings in the field suggest that CCT 
could benefit patients at risk for dementia. The current 
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study will build on these findings by implementing a 
study design with an active control group, a longer trial 
duration, an increased intensity of CCT, examination of 
generalisability to functional abilities beyond cognitive 
training skills, structural and fMRI assessment and rigor-
ously blinded methodology.
MEthods And AnAlysIs
study design features and rationale
One hundred patients clinically diagnosed with MCI will 
be randomised. There will be two sites: New York State 
Psychiatric Institute/Columbia University Medical Center 
(CUMC) in New York, NY (NYSPI as lead coordinating 
site) and Duke University Medical Center (DUMC) in 
Durham, NC. Patients will be randomised to one of two 
computerised cognitively stimulating exercises: cross-
word puzzle training (CPT) or a suite of exercises (CCT; 
memory tasks, matching tasks, spatial recognition tasks, 
processing speed tasks). These patients will be further 
randomised by MCI type (early MCI or late MCI), age (70 
and below or 71 and above) and site (NYSPI/CUMC or 
DUMC) as the stratification factors and will be followed for 
78 weeks. The randomisation sequences will be balanced 
in blocks of random size (2, 4) to prevent clinicians from 
guessing what the next patient’s treatment might be. The 
term ‘control’ will not be used in the consent form to 
reduce the participant’s expectancy bias.
To maintain neutrality and mitigate expectancy bias 
among patients, the informed consent form signed by 
all patients during the screening visit will not indicate 
which group is the active group (suite of exercises) or the 
control group (crosswords). Rather, it will indicate that 
the patient may be assigned to one of two cognitively stim-
ulating exercises, CCT or CPT.
role of sponsor
The study is funded entirely by the National Institute 
on Aging grant and supervised by a Data Safety Moni-
toring Board. Using Lumosity, a web-based gaming plat-
form from Lumos Labs, we customised a specific set of 
CCT and CPT training modules for participants to use 
in this trial. After a comprehensive review of several CCT 
modules on the market, we chose these modules from 
Lumosity due to their large selection of games tailored 
to specific cognitive domains, their research specific 
platform, availability of active control condition, avail-
ability of the online self-administered NeuroCognitive 
Performance Test (NCPT) and our previous pilot data 
in the elderly with this platform. Aside from providing 
the research platform and technical support at no cost, 
Lumos Labs provides no financial support for this study 
and their staff have no significant role in the final study 
design, study conduct, data interpretation or publication. 
Patients will not be required to pay for the platform and 
will not have a poststudy commitment to the platform. 
None of the study team has any financial conflicts with 
Lumos Labs.
recruitment, eligibility, consent
Patients will be recruited from the current patient case-
load of the investigators, referral by neurology, psychi-
atry, primary care, public health and geriatric medical 
clinics affiliated with the centres and supplemented by 
advertisement.
Inclusion/exclusion criteria
Detailed inclusion/exclusion criteria are described in 
box 1. Notable inclusion criteria will be age range restriction 
55–95 years, subjective cognitive complaints (ie, memory 
or other cognitive complaints, eg, naming/language), 
Wechsler Memory Scale-III (WMS-III) Logical Memory 
Story A delayed recall score 0-11, Folstein Mini Mental 
State Examination (MMSE) score ≥23 out of 30, availability 
of an informant and access to a home desktop or laptop 
computer with full access to the Internet for the study dura-
tion. Patients who have a history of major psychiatric or 
neurological illness including motor disorders like Parkin-
son’s disease, a dementia diagnosis of any type, contraindi-
cation to MRI scan, lack of English-speaking ability or have 
been defined as regular online brain training or regular 
crossword puzzle users (≥2 times per week in the past year) 
will be excluded. Depression will be assessed using the 
15-item Geriatric Depression Scale (GDS); a diagnosis of 
major depressive disorder is exclusionary.
MCI criteria
MCI and type of MCI (early MCI or late MCI) will be 
assessed by the delayed recall score of WMS-III Logical 
Memory and by the score on the MMSE. On Logical 
Memory II Story A, a score from 0 to 11 will indicate 
cognitive impairment per the Alzheimer’s Disease Neuro-
imaging Initiative criteria. MCI type will be determined 
from this score combined with years of education of the 
patient. Early MCI (eMCI) will be defined as a delayed 
recall score of 3–6 with 0–7 years of education, score of 
5–9 with 8–15 years of education and score of 9–11 with 
16 or more years of education. Late MCI (lMCI) will be 
defined as a delayed recall score of ≤2 with 0–7 years 
of education, score of ≤4 with 8–15 years of education 
and score of ≤8 with 16 or more years of education. For 
both eMCI and lMCI, everyday function must be well 
preserved for study inclusion. A MMSE score ≥23 will also 
be required to indicate mild cognitive impairment, and 
this is required for study inclusion.
length of clinical trial
Most transitions from MCI to AD typically occur within 
3 years of follow-up after the diagnosis of MCI is made.34 
We chose 18 months as the length of this clinical trial 
to decrease dropouts that can occur in a very long 
controlled trial. Since this study is considered low risk, we 
do not anticipate participants to suffer harm from trial 
participation.
treatment regimen
Enrolled participants will come to the clinic for five 
scheduled visits (weeks 0, 12, 32, 52 and 78) and will 
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box 1 Inclusion/exclusion criteria
Inclusion critera
1. Men and women 55–95 years of age (inclusive) at the time of in-
formed consent.
2. Subjective cognitive complaints, that is, memory or other cognitive 
complaints, for example, naming/language.
3. Meets criteria for cognitive impairment defined as scores>1 SD be-
low standardised norms on memory function as identified by the 
Wechsler Memory Scale III Logical Memory delayed recall score.
4. Folstein Mini Mental State score ≥23 out of 30.
5. A family member or other individual who is in contact with the pa-
tient and consents to serve as informant during the study; this could 
be a telephone informant in case of patients who do not have a live-
in informant or close significant other.
6. Access to a home desktop or laptop computer at acceptable speed 
for the study duration.
Exclusion criteria
1. Diagnosis of dementia of any type.
2. Current clinical evidence of schizophrenia, schizoaffective disorder, 
major depression, psychosis or bipolar I disorder (Diagnostic and 
Statistical Manual of Mental Disorders IV Text Revision (DSM-IV TR) 
criteria).
3. Active suicidal ideation or plan.
4. Current or recent (past 6 months) alcohol or substance use disor-
der (DSM-5 criteria).
5. Clinical stroke with residual neurological deficits. While we will not 
exclude patients with cerebrovascular disease, we will not include 
patients who have had a stroke with residual clinical deficits be-
cause it is not clear that this type of patient is similar to the MCI pa-
tient generally, and clear-cut neurological impairment, for example, 
hemiplegia/hemiparesis or speech impairment, may compromise 
the patient’s ability to do the computerised cognitive training or 
active control procedures and to complete the neuropsychological 
tests.
6. Use of medications known to have a negative impact on cognition: 
benzodiazepines in lorazepam equivalents greater than or equal 
to 1 mg/day, narcotics, anticholinergics. Other patients receive 
medications that may be associated with cognitive impairment 
but are rarely considered the likely etiologyaetiology, for example, 
theophylline, nifedipine, beta blockers; they will not be excluded. 
Patients receiving other psychotropic medications not expected to 
have a material impact on cognition, for example, Selective ser-
otonin reuptake inhibitors (SSRIs) and Serotonin-norepinephrine 
reuptake inhibitors (SNRIs) will be eligible.
7. Presence of any of the following disorders: (a) central nervoussys-
tem infection, with cerebrospinal fluid evidence of meningitis, en-
cephalitis or other infectious process; (b) dementia of any type; 
(c) Huntington’s disease; (d) multiple sclerosis; (e) Parkinson’s dis-
ease; (f) other neurological disorders with focal signs, for example, 
amyotrophic lateral sclerosis; (g) mental retardation.
8. Acute, severe unstable medical illness. For cancer, acutely ill pa-
tients (including those with metastases) will be excluded, but histo-
ry of successfully treated cancer will not result in exclusion.
9. Contraindication to MRI scan: pacemaker, metal implants following 
surgery, any other contraindication to MRI. Eligibility for the MRI 
scan is a requirement for the study.
10. University of Pennsylvania Smell Identification Test (UPSIT) ex-
clusions: current smoker >1 pack daily, current upper respiratory 
infection (retested as soon as the infection clears). UPSIT scores 
Continued
box 1 Continued
are reduced in schizophrenia, Parkinson’s disease and Parkinson’s-
related conditions; these disorders are exclusion criteria for this 
study. Patients with UPSIT exclusions will not receive the UPSIT but 
will continue to participate in all other aspects of the study.
11. Patients lacking English-speaking ability as determined by self-re-
port and clinical evaluation.
12. Regular online brain training or regular crossword puzzle user, de-
fined as doing these procedures at a frequency of twice weekly or 
greater during the year prior to screening. Eligible participants who 
join the trial are instructed not to do these procedures on their own 
during the trial, that is, independent of the study.
13. Participation in another intervention trial for cognitive impairment.
receive at least three scheduled phone calls with research 
staff (weeks 20, 42, and 64). Participants will be enrolled 
into the study after screening for eligibility and consent 
is signed. The randomisation will be assigned by the stat-
istician and then carried out by the unblinded research 
coordinator, with individuals stratified by MCI type, age 
group and site.
Randomisation
The blinded research coordinator (at NYSPI or Duke) 
will complete the training group randomisation form 
to indicate the following information for the patient: 
site, age, and MCI type. This form will be verified by the 
unblinded research coordinator at NYSPI, who will then 
assign a study identification (ID) to that patient, using a 
prepopulated form from the statistician’s randomisation 
assignment. The order of the study ID assignment will 
determine which study condition the patient will receive: 
CPT or CCT. The Lumosity account information will be 
generated after the MRI has been completed and quality 
checked. Lumosity account credentials will include 
a research-specific COGIT ID (cognitive impairment 
training identification) email address and password, 
which will enable users to log into an account specific to 
their study condition.
Randomisation will be complete when the patient logs 
into his/her account for the first time at the baseline visit 
and sees which condition he/she is in. At this visit, patients 
will be trained by unblinded study staff in their assigned 
training condition. Eighteen modules were selected to 
target various cognitive domains: (1) memory (tidal trea-
sures, familiar faces, memory matrix); (2) processing 
speed (speed match); (3) response inhibition (colour 
match); (4) verbal fluency/vocabulary proficiency (word 
bubbles, word snatchers, editor’s choice, continuum); (5) 
planning/divided attention (train of thought, brain shift, 
trouble brewing, disillusion); (6) visual interference (lost 
in migration, ebb and flow, masterpiece); (7) identifica-
tion (river ranger); (8) visualisation (speed pack). These 
cognitive domains were chosen as they are areas that are 
often impaired in patients with MCI and thus represent 
areas that can be targeted for improvement.35 Verbal 
fluency and vocabulary proficiency tasks were included 
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Table 1 Complete list of CCT game battery and associated 
cognitive domains (provided by Lumos Labs)
Game name Cognitive domain
Tidal Treasures Working memory
That is, delayed, non-matching to 
sample; self-ordered pointing
Speed Match Processing speed
Colour Match Response inhibition
Word Bubbles Verbal fluency
Train of Thought Planning
Divided attention
Multiple attractions
Familiar Faces Episodic memory; verbal memory 
and learning
Memory matrix Episodic memory; visuospatial 
memory
Lost in migration Visual interference
Brain shift Task switching
Trouble brewing Multitasking, divided attention, 
sustained attention, planning, 
working memory
Ebb and flow Task switching, semantic and 
visual interference
Masterpiece Mental rotation; visualisation; 
spatial reasoning
River ranger Identification
Word Snatchers Vocabulary proficiency
Speed Pack Visualisation
Disillusion Task switching
Editor’s choice Vocabulary proficiency
Continuum Vocabulary proficiency
to promote verbal fluency in the CCT group. Further, 
the episodic memory task, familiar faces, targets verbal 
memory and learning. With this, it is acknowledged that 
episodic memory training may be somewhat limited in 
the selected battery of modules provided by Lumosity. 
Each CCT session will consist of a random selection of 
six modules. Participants in the CCT condition are not 
allowed to choose the games and are not allowed to skip 
over or change the suite of games. The Lumosity platform 
will scale difficulty by using the patient’s Lumosity Perfor-
mance Index (LPI). The LPI will consider three areas for 
each patient. The Game Performance Index (GPI) will 
be determined by reviewing score distributions for each 
game. The Cognitive Area Performance Index (speed, 
memory, attention, flexibility and problem solving) will 
be calculated using a weighted average of the Game 
Performance Index. Third, the overall Cognitive Perfor-
mance Index will be calculated using a weighted average 
of the GPIs from all cognitive areas. A complete list of 
selected CCT games are described in table 1. Crosswords 
engage primarily verbal abilities and perhaps, executive 
and attentional mechanisms. The Lumosity games target 
different cognitive domains, such as speed of processing 
and memory, as well as verbal abilities. The effect that 
these different trainings have on the so-called far transfer 
problem will of course be of major interest. There should 
be no case in which an emergency unblinding will need 
to take place, as the blinded intervention is a computer-
ised intervention.
Participants in the CCT group and the CPT group will 
spend the same amount of time on the platform during 
the intensive training phase, which will consist of four 
30-min training sessions per week for 12 weeks. Partici-
pants are not required to have any particular level of 
computer skills for study inclusion; however, at the initial 
baseline training, all participants will be trained on how 
to successfully access the training platform and how they 
could obtain help both from research staff and their infor-
mant throughout the study. For both groups, responses 
will be entered via mouse and keyboard. For the CPT 
group, questions will not need to be completed in order, 
and there will not be any feedback for the accuracy of 
the response at the time of entry by the participant. On 
completion of the CCT suite of exercises after 30 min, 
participants will receive a score. Similarly, after 30 min, 
the crossword training will automatically end. If a partici-
pant were to finish an entire crossword puzzle before the 
30 min cut-off, they would be directed to another cross-
word puzzle to ensure they complete a total of 30 min.
Following the intensive training phase of 12 weeks, 
participants will be instructed to complete six booster 
sessions. Each booster session will consist of four CCT/
CPT sessions. Booster sessions will be completed at 
weeks 20, 32, 42, 52, 64 and 78. At weeks 32, 52 and 78, 
patients will complete three booster sessions at home and 
complete the fourth session in-clinic with research staff. 
At weeks 20, 42 and 64, patients will complete all four 
booster sessions at home. Generally, in previous cogni-
tive training studies, booster sessions have been limited. 
For instance, the ACTIVE trial had two booster sessions, 
each consisting of four 75-min trainings at 11 and 35 
months. During the course of the trial, booster sessions 
included a total of 8 trainings, for a total of 10 hours.6 
In contrast, COGIT will have 6 booster sessions (24 total 
training sessions each lasting 30 min) over 15 months. 
Thus, COGIT will include 12 hours total for booster 
sessions during the trial. The ACTIVE trial only required 
compliant participants to complete the booster sessions, 
whereas all participants will complete booster sessions in 
the COGIT study.6
Clinic-based cognitive, functional and smell assessments
At baseline (week 0), the Alzheimer’s Disease Assess-
ment Scale-Cognition Subscale 11 (ADAS-Cog 11) will be 
administered, in addition to the following neuropsycho-
logical test battery: Wechsler Adult Intelligence Scale-III 
Block Design (to assess visuospatial skills), Digit Symbol 
Substitution Test (DSST) (to assess attention), Trail 
Making A & B (to assess attention and executive func-
tion), Verbal Fluency and 15-item Boston Naming Test (to 
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assess language), Auditory-Verbal Learning Test (to assess 
verbal learning and memory) and WMS-III Visual Repro-
duction Test (to assess nonverbal learning and memory). 
In addition, the UPSA and University of Pennsylvania 
Smell Identification Test (UPSIT) will be administered. 
Testing fatigue is mitigated by allowing participants to take 
breaks during the testing. If there is missing data from 
one time point, the study team will attempt to bring the 
participant back to the clinic within the allowed window 
to complete missing measures. The FAQ will be adminis-
tered to the patient’s informant, either during the study 
visit or shortly after the visit over the phone.
Self-Administered cognitive test battery
Another unique aspect of the study is the use of the NCPT, 
an online, computerised, self-administered battery devel-
oped by Lumosity. It will test various cognitive domains 
outlined in the Study Measures section. The NCPT will 
allow us to examine the efficacy of a self-administered test, 
in combination with standardised, clinic-based neuropsy-
chological tests.
timeline of longitudinal assessments
At in-clinic visits (baseline and weeks 12, 52 and 78), 
the same neuropsychological battery of testing will be 
completed. At the week 12 and week 78 visits, the patient 
will be asked to complete the User Engagement Scale, 
which will be adapted to capture usage of a computerised 
platform. This scale will measure aspects of engagement, 
usability and satisfaction with the computerised platform 
on a 5-point Likert scale. Week 20 will be a phone inter-
view between study physician/neuropsychologist and 
patient to follow-up on how the patient has been doing 
and to remind the patient to complete a booster session.
blinded training procedure
The blinded research coordinator will administer the full 
neuropsychological test battery, including the UPSA and 
FAQ. The blinded clinician will complete the Diagnosis 
Form and the Contributing Features to MCI form after 
clinical interview and review of the neuropsychological 
testing. The unblinded research coordinator will admin-
ister the initial computerised training and all subsequent 
booster sessions to patients in the clinic. To track type 
of games/crossword puzzles and amount of time that 
the subject spends doing the games/crossword puzzles, 
only unblinded study coordinators receive reports from 
Lumosity each week. If the Lumosity reports of computer 
games/crosswords access do not match the subject's 
assigned instructions, the unblinded coordinator then 
contacts the subject to guide and ensure adherence to 
the protocol.
hypotheses
See figure 1 for a conceptual model of specific study aims 
and outcome measures. The primary aim of the study is 
to assess change in cognitive and functional status over 
18 months in patients with MCI comparing the CCT and 
CPT groups. Hypothesis 1: Patients with MCI randomised 
to CCT will show better cognitive outcomes on the 
ADAS-Cog 11 (primary outcome measure), Neuropsy-
chological Testing Composite score (secondary outcome 
measure) and NCPT (exploratory outcome measure) 
compared with active control (CPT). Hypothesis 2: 
Patients with MCI randomised to CCT will show better 
functional outcomes as assessed by the UPSA (primary 
functional outcome) and FAQ (secondary functional 
outcome) by the end of the 18-month trial compared with 
active control. Hypothesis 3: brain pathology (smaller 
hippocampal volumes, lower odour identification scores 
on the UPSIT, ApoE e4 allele present) will moderate the 
relationship between treatment assignment and cognitive 
and functional outcomes.
The secondary aim of the study is to examine the effects 
of CCT on resting-state DMN connectivity as well as other 
networks modulated by CCT effects. Hypothesis 1: MCI 
patients randomised to CCT will demonstrate greater 
change in an index of DMN functional connectivity 
compared with patients randomised to active control. 
Hypothesis 2: indicators of brain pathology (smaller 
hippocampal volumes, lower odour identification scores 
on the UPSIT, ApoE e4 allele present) will moderate the 
relationship between change in the DMN and treatment 
assignment.
The tertiary aim of the study is to examine differ-
ences in rates of progression to dementia and AD in the 
two randomised treatment groups, recognising that if 
progression to these outcomes is uncommon there will be 
insufficient statistical power. Hypothesis 1: the proportion 
converting to dementia will be lower in the CCT group 
compared with active control.
study measures
Study measures with time-points of administration are 
listed in table 2. The MMSE will be administered at screen 
and each subsequent in-clinic visit using five different 
versions of the three-word recall item to reduce prac-
tice effects.36 The Cumulative Illness Rating Scale for 
Geriatrics and The Framingham Stroke Risk Scale will 
be completed by the study physician at screen to assess 
for cardiovascular disease risk factors and other medical 
conditions.
The GDS will be administered at screen and each 
subsequent in-clinic visit to assess for depression. If GDS 
is greater than five at any visit, the patient will be evalu-
ated by a psychiatrist and an appropriate clinical referral 
will be made, if needed, for treatment of depression. The 
Cognitive Reserve Index is a brief questionnaire that will 
be administered by the research coordinator at screen 
and will evaluate the cognitive reserve of an individual by 
means of the compilation of information as it relates to 
his/her adult life.
At screen, the research coordinator will be responsible 
for administering the History of Game Use Question-
naire, Physical Activity Assessment and WMS-III Logical 
Memory I and II. The History of Game Use Question-
naire will be administered again at weeks 12 and 78 to 
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Figure 1 Conceptual model in the intervention phase patients are randomly assigned to either CCT or CPT. To evaluate 
cognitive status, the primary outcome measure will be the ADAS-Cog 11, the secondary outcome measure will be the 
neuropsychological testing composite score and the exploratory outcome measure will be the neurocognitive performance 
test. To evaluate functional status, the primary outcome measure will be the UPSA and the secondary outcome measure will 
be the FAQ. To evaluate changes in neural circuitry, the primary outcome measures will include hippocampal volume (MRI) and 
DMN connectivity (fMRI). AD, Alzheimer’s disease; ADAS-Cog, 11 Alzheimer’s Disease Assessment Scale—Cognitive Subscale 
11; CCT, computerised cognitive training; CPT, crossword puzzle training; DMN, default mode network; FAQ, Functional 
Assessment Questionnaire; fMRI functional MRI; MCI mild cognitive impairment; UPSA UCSD Performance-Based Skills 
Assessment.
ensure that patients are not partaking in any other types 
of cognitive training games while in the study.
At screen and week 78, patients will undergo an MRI 
scan of the brain. The MRI scan will include the following 
sequences: Localiser, high-resolution T1-weighted 
Inversion recovery prepped 3DSPGR (spoiled gradient 
recalled), and T2 FLAIR (fluid attenuated inversion 
recovery) and GE-EPI (General Electric echo-planar 
imaging) resting-state fMRI scans.
At weeks 0 and 78, the UPSIT will be completed by 
the patient, which is a 40-item scratch and sniff multi-
ple-choice olfactory identification test.
At each in-clinic visit, apart from week 32, the ADAS-Cog 
11 and full neuropsychological test battery will be admin-
istered. The NCPT will be administered at weeks 0, 12 
and 78. The cognitive domains measured by the NCPT 
are memory (visuospatial working memory, short-term 
memory), processing speed (visual search, psychomotor 
speed), problem solving (logical reasoning, numerical 
calculation), attention (selective, divided) and flexibility 
(response inhibition, task switching). The assessments, 
10 total ‘subtests’, are online adaptations of widely used 
neuropsychological tests whose test properties are not 
affected by shifting to computerised administration.37
The neuropsychological test battery includes: 
WAIS-III Block Design, DSST, Trail Making A and B, 
Verbal Fluency and 15-item Boston Naming Test, Audi-
tory-Verbal Learning Test (AVLT) and WMS-III Visual 
Reproduction Test. For word learning lists, the neuro-
psychological testing materials provide different but 
parallel word lists, so as to avoid practice effects in MMSE 
and ADAS-Cog, but not for AVLT. With respect to the 
latter, we did not adopt this approach because we were 
concerned that different forms have not been estab-
lished as equivalent in difficulty level. The UPSA will be 
administered only at weeks 0, 32 and 78 due to the high 
tendency for practice effects. It is a performance-based 
measure of functional abilities that includes measures of 
simulated real-world activities; for example, planning a 
trip to the beach, remembering documents to bring to 
a medical appointment and dialling a phone number. 
When a participant wears corrective lenses during the 
testing battery, this is documented in the participant’s 
research chart.
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ADAS-Cog11 X X X X
ApoE and blood test X
CIRS-G X X
Cognitive Reserve Index X
Cognitive Training or Control training booster 
session
X X X X X X X
Contributing features to MCI X X X
Demographics history (patient tracking form) X
Diagnosis form X X X
Digit Symbol Substitution Test X X X X
Expectancy Scale (participant and informant) X X X
Family history X
FAQ X X X X X X
Framingham Stroke Risk X
Geriatric Depression Scale X X X X X





Medications (chart list and database list) X X X X X
MMSE X X X X X
MRI scan of brain X X
NCPT online cognitive performance test X X X
Neuropsychological Battery: AVLT, block 
design, verbal fluency, visual reproduction, 
boston naming test, trails A and B
X X X X
Physical activity assessment X
UPSA X X X
UPSIT X X
User Engagement Scale X X
WMS-III Logical Memory I and II X
ADAS-Cog 11, Alzheimer’s Disease Assessment Scale—Cognitive Subscale 11; AVLT, Auditory Verbal Learning Test; ApoE, Apolipoprotein E gene; 
CIRS-G, Cumulative Illness Rating Scale for Geriatrics; FAQ, Functional Assessment Questionnaire; MCI, mild cognitive impairment; MMSE, Mini 
Mental Status Examination; NCPT, NeuroCognitive Performance Test; UPSA, UCSD Performance-Based Skills Assessment; UPSIT, University of 
Pennsylvania Smell Identification Test; WMS-III, Wechsler Memory Scale-III.
At screen and weeks 12, 32, 52 and 78, the participant will 
meet with the study physician or the neuropsychologist to 
assess for illness progression and adverse events. Adverse 
events that are spontaneously reported to research coor-
dinators at any clinic visit will be discussed with the study 
physician or the neuropsychologist to determine how to 
proceed. Adverse events and subsequent steps to deal 
with the adverse events will be documented in the patient 
chart, and serious adverse events will be reported to the 
Data Safety and Monitoring Board and study sponsor, 
National Institute on Aging.
Additionally, the research coordinator will conduct an 
interview with the informant at, or shortly after, each visit 
to complete the FAQ.
Criteria for early discontinuation
We expect early discontinuation to occur because of one 
or more of the following reasons: (1) the patient’s deci-
sion not to continue the computerised training (CCT 
or CPT) due to lack of interest, motivation or available 
time; (2) unavoidable circumstances, e.g., moving resi-
dence and unwillingness to return for in-person evalu-
ations; (3) investigator decision to terminate; (4) death 
or prolonged hospitalisation for medical reasons. We will 
not terminate participation for non-adherence because 
even if the patient is non-adherent to the protocol, we 
will document level of adherence (done electronically in 
this computerised training protocol) and still include the 
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patient’s data in the analyses based on the intent-to-treat 
principle.
data management
Data entry will be completed by programme managers, 
clinical research coordinators, and research assistants 
on the study protocol. Data entry/cleaning will be done 
throughout the project. The data collected in this study 
will be monitored by the Data Coordinating Center at 
NYSPI. The unit will work closely with the research assis-
tant/coordinator and the principal investigator to facil-
itate independent auditing of primary subject records. 
The database will provide reports indicating all modi-
fications that have been made in the database together 
with paper communications (fax, e-mail) confirming and 
authorising these modifications. Access to the data system 
is available only to authorised users, with multiple levels 
of security including user ID/password authentication via 
Microsoft Active Directory overseen by experienced IT 
personnel. Other authorised users with direct access to 
the data system will be Data Coordinating Center (DCC) 
staff. DCC data-related operations and the Scientific 
Information Retrieval/Citrix system have been certified 
by Columbia University’s Information Security Office. 
The dataset will not be published in a data repository.
Genetic testing
Apolipoprotein E (ApoE) genetic analysis on a blood 
sample will be done through the laboratory of the Human 
Genetics Resources Core at Columbia University Medical 
Center. We will assess the ApoE ε4 allele as potentially 
associated with response to CCT; a prior trial found an 
association between the ε4 allele and cognitive improve-
ment on donepezil.38
Concomitant medications
Putative cognitive enhancers, narcotics, all classes of 
psychotropic medications and over 20 other classes of 
commonly prescribed and over-the-counter (and alter-
native) medications will be documented in a rating form 
at screen and subsequent in-clinic visits. An exclusion 
criterion will the be daily use of medications known to 
have a negative impact on cognition: high-dose narcotics, 
anticholinergics and benzodiazepines in lorazepam 
equivalents ≥1 mg/day. During the first 12 weeks of the 
study, the intensive cognitive training phase, patients 
are encouraged not to change any of their medications, 
unless clinically indicated.
statistical analysis and sample size
We powered our trial to detect an effect size at 18 months 
of d=0.58 (80% power). This effect size is more conser-
vative than published treatment changes associated with 
CCT (for instance, see reference 39). We assume that 
dropout is distributed uniformly across waves of follow-up 
assessments (with 5% attrition between each consecu-
tive pair of the 5 major time-points, that is, 20% by 18 
months).
Outcome measures (primary and secondary hypotheses testing)
Aim 1 hypothesis 1 and 2. Patients with MCI on CCT will 
show a lower rate of cognitive and functional decline 
compared with patients with MCI on active control by the 
end of the 18-month trial. We will use generalised linear 
mixed effects models of cognitive and functional measures 
collected repeatedly across the 78 weeks according to the 
schedule (table 2). For example, cognitive measure ik = 
β0 + β1 Timeik + β2 Groupi +β3 (Groupi x Timeik) + v0i + 
v1i Timeik + εik where Groupi indicates treatment group 
for subject i (group=1 CCT, 0 for control), k=time (base-
line, 12 weeks, 20 weeks, 52 weeks, 78 weeks) and v0i is a 
subject-specific random intercept. Time will be treated as 
categorical if linearity is not plausible and group effects 
at 18 months can be tested by forming contrasts from the 
fitted model. Potential site differences will be evaluated 
using descriptive statistics, and site will be included in all 
analyses as a covariate, as will other stratification variables 
including age group and MCI type at baseline.
Aim 2 hypothesis 1. Patients with MCI randomised to 
CCT will demonstrate either more of an increase or less 
of a decrease in DMN connectivity (goodness-of-fit index 
scores) compared with patients randomised to active 
control. To test this hypothesis, we will use a repeated 
measures analysis of covariance (ANCOVA) with time 
(baseline vs post-treatment) as the repeated measure, 
DMN connectivity as an outcome, treatment condition 
(CCT vs CPT) as a predictor, and site, age and MCI status 
at baseline as covariates.
Moderating effects in aim 1 hypothesis 3 and aim 2 
hypothesis 2. As a part of our exploratory analyses, we will 
examine specific potential moderators: ApoE ε4 allele, 
MRI indices, UPSIT. To show, for example, that baseline 
hippocampal volume is a moderator, we will test its inter-
active effect with treatment on outcomes. Moderator and 
moderator-interaction terms can be easily accommodated 
in the mixed effects regression models described in aim 
1. Hypotheses 1 and 2. A similar approach will be used by 
adding moderator and moderator x group interactions to 
the ANCOVA described in aim 2 hypothesis 1. The results 
must be interpreted with the caveat that there may not be 
enough power to assess these interactions, especially for 
moderators with low prevalence.
Aim 3 hypothesis 1. The proportion diagnosed with 
dementia during follow-up will be lower in the CCT group 
compared with active control. Logistic regression will be 
used to test the binary outcome of dementia status at 18 
months predicted by treatment group controlling for site, 
age group and MCI type at baseline.
Missing data is managed statistically through use of 
mixed model repeated measures analyses.
sample size
A power analysis was conducted using the RMASS program 
for longitudinal studies, which determined that a total 
sample size of 100 participants will provide a sufficient 
effect size to evaluate our hypotheses. We have two primary 
outcome measures (ie, multiple outcome measures), 
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namely ADAS-Cog and the UPSA. For multiple outcome 
measures, statistical significance on any one measure is 
meaningful, and there is no need to correct for multiple 
comparisons (unlike coprimary outcome measures). All 
other outcome measures are secondary and exploratory.
Patient and public involvement
Patients will first be involved in the research after study 
design is finalised by the study investigators. At this stage, 
patients will be referred by physicians or self-referred 
from online and newspaper advertisements for their 
initial screening visit. The patients will not be involved 
in study design, study recruitment or conduct, or dissem-
ination of study results. We will assess the burden of the 
trial intervention on patients using the User Engagement 
Scale and the Participant/Informant Expectancy Scales. 
Patients will not be invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients will not 
be invited to contribute to the writing or editing of this 
document for readability or accuracy.
Ethics
All COGIT patients at entry will be required to have the 
capacity to provide informed consent and sign the Insti-
tutional Review Board (IRB)-approved informed consent 
form. Local IRB and state regulations for consent will be 
followed. Patient confidentiality as it pertains to poten-
tial and enrolled participants before, during and after 
the trial will be collected, shared and maintained strictly 
according to Health Insurance Portability and Account-
ability (HIPAA) law.
Important protocol modifications will be communi-
cated to the Data Safety and Monitoring Board, NYSPI 
IRB and Duke University IRB and updated online for trial 
registries.
The research data on specific moderators, including 
UPSIT and ApoE genotyping, will not be not released to 
the patient, and this will be specified in the consent form. 
The cognitive testing results and clinical reading of the 
MRI scan will be released to the patient (and the patient’s 
primary physician, if requested); the MRI research volu-
metric ratings and fMRI findings will not be released.
data safety and Monitoring board
Three National Institute on Aging-approved independent 
experts with expertise in conducting clinical trials in mild 
cognitive impairment will form the Data Safety and Moni-
toring Board (DSMB). All serious adverse events (SAEs) 
will be reported to the DSMB. The DSMB will audit the 
trial conduct, review all SAEs, participate in a telecon-
ference twice a year to determine if the study should 
continue and then will provide an actionable report to 
the principal investigator. This process will be indepen-
dent from the investigators.
dissemination
The study results will be disseminated through publica-
tions and conference presentations as well as on public 
websites, including  clinicaltrials. gov. Researchers will be 
eligible for authorship after consideration by the prin-
cipal investigators; no professional writers will be used.
significance
This will be one of the first investigator-blinded and 
controlled long-term trials to evaluate the effects of 
home-based CCT versus computerised CPT on cogni-
tive, functional, hippocampal and default mode network 
connectivity neural outcomes in MCI. Positive results 
from this pilot trial may support the further development 
of home-based cognitive training and self-assessments in 
people at risk for dementia.
The results will help inform the design of a more 
powerful randomised controlled trial in many ways: 
determine sample size for a multicenter trial, identify 
subgroups more likely to benefit, identify subdomains 
and exercises most likely to improve, optimise training 
dose and duration, learn how subjects engage, identify 
gender effects, model slopes and long-term benefits, 
assess value of a self-administered cognitive test, under-
stand brain networks affected and examine the potential 
moderating role of ApoE ε4 status on CCT outcome.
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